Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration

SAN DIEGO and CAMBRIDGE, Mass., April 28 /PRNewswire/ -- ChemDiv, Inc., a global CRO for drug discovery & development, and Syndexa Pharmaceuticals Corporation, a biopharmaceutical company developing first-in-class drugs for the treatment of metabolic diseases, have announced today the signing of a collaborative discovery research agreement. Under the terms of the agreement, ChemDiv will discover small molecule ligands for biotargets nominated by Syndexa. Financial terms of the collaboration were not disclosed.

"We are very excited to deploy our discovery resources in this collaboration with Syndexa," said Dr. Ilya Okun, VP of Biology & CTO at ChemDiv, Inc. "ChemDiv's flexible service capabilities emphasize delivery of rapid, high-value results for our partners' drug discovery programs. We are able to realize that goal through the creative integration of the chemistry and biology components of our Discovery outSource(TM) platform."

"We are extremely pleased to be working with ChemDiv, a drug discovery partner with a strong track record. The collaboration will provide us with access to high quality screening capabilities and compound library resources. We anticipate that this project will accomplish our goal of discovering promising drug leads to enhance our R&D pipeline," said Teo Uysal, President and CEO, Syndexa Pharmaceuticals.

About ChemDiv, Inc.:

ChemDiv, Inc. (Chemical Diversity) is a global CRO delivering discovery opportunities and services for life science partners. ChemDiv is merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. Drawing on a long heritage in small-molecule chemistry research, a dedicated and personal approach to collaborative research and development as well as world class personnel and physical resources, ChemDiv provides partners with access to Discovery outSource(TM) a full service drug discovery offering encompassing synthetic chemistry; medicinal chemistry, diverse & focused screening libraries, global logistics and wide range of biology services for pre-clinical discovery & development projects. http://www.chemdiv.com

About Syndexa Pharmaceuticals Corporation:

Syndexa is engaged in the discovery and development of a new generation of small-molecule drugs that target the biological interface between inflammatory and metabolic pathways, and provide a novel mechanism for the treatment and prevention of metabolic diseases including obesity, type 2 diabetes and atherosclerosis. Syndexa's current programs include the development of inhibitors of obesity-induced Endoplasmic Reticulum (ER) stress and c-jun N-terminal kinase (JNK). Founded by leading scientists from Harvard and University of California, San Diego, the company is executing on its business strategy to rapidly build and commercialize a portfolio of breakthrough products. The company is headquartered in Cambridge, MA. For additional information, please visit http://www.syndexa.com.

SOURCE ChemDiv, Inc.; Syndexa Pharmaceuticals Corporation

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.